Cases & Deals

  • Home
  • Practices
  • TxCell completes €8 million private placement of new shares

Share

TxCell completes €8 million private placement of new shares

July 2015

Client(s) TxCell SA

Jones Day advised TxCell SA, a biotech company specializing in innovative, personalized cell-based immunotherapies, as well as Bryan, Garnier & Co. as global coordinator and bookrunner, in connection with its €8 million (US$9 million) private placement of new shares to institutional investors.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.